New coeliac disease treatments and their complications

被引:13
作者
Vaquero, Luis [1 ]
Rodriguez-Martin, Laura [1 ]
Leon, Francisco [2 ]
Jorquera, Francisco [1 ,3 ]
Vivas, Santiago [1 ,3 ]
机构
[1] Complejo Asistencial Univ Leon, Serv Aparato Digest, Leon, Spain
[2] Celimmune, Bethesda, MD USA
[3] Univ Leon, Inst Biomed IBIOMED, Leon, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2018年 / 41卷 / 03期
关键词
Coeliac disease; Gluten-free diet; Gluten-sensitive enteropathy; T-CELL LYMPHOMA; GLUTEN-FREE DIET; INTESTINAL BARRIER FUNCTION; NF-KAPPA-B; ALPHA-GLIADIN; 1ST-DEGREE RELATIVES; LARAZOTIDE ACETATE; CROHNS-DISEASE; TISSUE TRANSGLUTAMINASE; THERAPEUTIC STRATEGIES;
D O I
10.1016/j.gastrohep.2017.12.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The only accepted treatment for coeliac disease is strict adherence to a gluten-free diet. This type of diet may give rise to reduced patient quality of life with economic and social repercussions. For this reason, dietary transgressions are common and may elicit intestinal damage. Several treatments aimed at different pathogenic targets of coeliac disease have been developed in recent years: modification of gluten to produce non-immunogenic gluten, endoluminal therapies to degrade gluten in the intestinal lumen, increased gluten tolerance, modulation of intestinal permeability and regulation of the adaptive immune response. This review evaluates these coeliac disease treatment lines that are being researched and the treatments that aim to control disease complications like refractory coeliac disease. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:191 / 204
页数:14
相关论文
共 117 条
  • [41] Mechanisms of Disease: immunopathogenesis of celiac disease
    Jabri, Bana
    Sollid, Ludvig M.
    [J]. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (09): : 516 - 525
  • [42] HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer:: Results from the European genetics cluster on celiac disease
    Karell, K
    Louka, AS
    Moodie, SJ
    Ascher, H
    Clot, F
    Greco, L
    Ciclitira, PJ
    Sollid, LM
    Partanen, J
    [J]. HUMAN IMMUNOLOGY, 2003, 64 (04) : 469 - 477
  • [43] Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study
    Kelly, C. P.
    Green, P. H. R.
    Murray, J. A.
    DiMarino, A.
    Colatrella, A.
    Leffler, D. A.
    Alexander, T.
    Arsenescu, R.
    Leon, F.
    Jiang, J. G.
    Arterburn, L. A.
    Paterson, B. M.
    Fedorak, R. N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) : 252 - 262
  • [44] The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate
    Khaleghi, Shahryar
    Ju, Josephine M.
    Lamba, Abhinav
    Murray, Joseph A.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (01) : 37 - 49
  • [45] Gluten: a two-edged sword. Immunopathogenesis of celiac disease
    Koning, F
    Gilissen, L
    Wijmenga, C
    [J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2005, 27 (02): : 217 - 232
  • [46] Celiac disease: Caught between a rock and a hard place
    Koning, F
    [J]. GASTROENTEROLOGY, 2005, 129 (04) : 1294 - 1301
  • [47] Current and novel therapeutic strategies in celiac disease
    Kurada, Satya
    Yadav, Abhijeet
    Leffler, Daniel A.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (09) : 1211 - 1223
  • [48] Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease
    Lahdeaho, Marja-Leena
    Kaukinen, Katri
    Laurila, Kaija
    Vuotikka, Pekka
    Koivurova, Olli-Pekka
    Karja-Lahdensuu, Tiina
    Marcantonio, Annette
    Adelman, Daniel C.
    Maki, Markku
    [J]. GASTROENTEROLOGY, 2014, 146 (07) : 1649 - 1658
  • [49] Lammers KM, 2008, GASTROENTEROLOGY, V135
  • [50] Leffler DA, 2015, GASTROENTEROLOGY, V148